pCDCAR1 CD19 h(4γ), NK(CAR-NK-2-M328-4G)
The vector of anti-CD19 chimeric antigen receptor(CAR) is constructed for the engineering of NK cells to target Human CD19. The NK cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD19 antibody linked to CD4 transmembrane domain and FcεRIγ signaling domains. And the vector product was designed for the treatment of chronic lymphocytic leukemia (CLL).
Targeting Cell Type
Chronic lymphocytic leukemia (CLL)
Discription of Signaling Cassetes
Cluster of Differentiation 4 (CD4) is a glycoprotein expressed on the surface of T helper cells, regulatory T cells, monocytes, macrophages and dendritic cells, and plays an important role in the development and activation of T cells. On T cells, CD4 is the co-receptor for the T cell receptor (TCR), and these two distinct structures recognize the Antigen-Major Histocompatibility Complex (MHC). CD4 signaling in CAR ensures specificity of the TCR-antigen interaction, prolongs the contact between the T cell and the antigen presenting cell and recruits the tyrosine kinase Lck, which is essential for T cell activation.
The high-affinity IgE receptor, also known as FcεRI, or Fc epsilon RI, is the high-affinity receptor for the Fc region of immunoglobulin E (IgE). FcεRI is a key molecule involved in allergic reactions. It is a tetramer composed of 1alpha, 1 beta, and 2 gamma chains. The gamma chains are also subunits of other Fc receptors. The scFv-based CARs engineered to contain a signaling domain from FcεRIγ have been shown to deliver a potent signal for T cell activation and function.
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T cell surface antigen Leu-12; B-lymphocyte surface antigen B4; Chronic Lymphocytic Leukemia; CLL; scFv; CD28; Leukemia; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; FMC63
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Lenti-CD19 CAR (scFv-CD28-CD27-FcεRIγ, 47G4) Viral Particle
||Anti-CD19 (104877) h(41BB-CD3ζ) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-CD28-41BB-CD3ζ, S2) Viral Particle
||Lenti-CD19 CAR (scFv-CD8-CD3ζ, FMC63) Viral Particle
||Anti-CD19 (104876) h(41BB-CD3ζ) CAR, pCDCAR1
||Anti-CD19 scFv h(41BB-CD3ζ) CART, pCDCAR1
||Anti-CD19 (Coltuximab) h(41BB-CD3ζ) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-41BB-CD3ζ, 105974) Viral Particle
||Lenti-CD19 CAR (scFv-CD3ζ, SJ25C1) Viral Particle
||Anti-CD19 (FMC-63) h(t2B4) CAR, pCDCAR1